1. Home
  2. Directory
  3. California
  4. Los Angeles
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1619086568

MICHAEL B VAN SCOY-MOSHER M.D.
Prescription History 1619086568
Internal Medicine - Hematology & Oncology in Los Angeles, CA


Quality Rating: 100 out of 100 score

NPI Status: Active since August 30, 2006

Contact Information

8635 W 3RD ST
STE 790W
LOS ANGELES, CA
ZIP 90048
Phone: (310) 659-9397
Fax: (310) 854-3028

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MICHAEL B VAN SCOY-MOSHER M.D., an active Hematology & Oncology specialist practicing in Los Angeles, CA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 288 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 192 claims alone.

Medication Index

A
E
I
L
R
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 192
30-Day Fills 504.7
Days Supply 15,106
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills165.7
Peer Average Days Supply4,950
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 182.4% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,311.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.66

State Avg Cost Per Claim

$27.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 82.0
Days Supply 2,460
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills59.9
Peer Average Days Supply1,785
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 25.9% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,389.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$305.57

State Avg Cost Per Claim

$259.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 672
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply769
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $376,199.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,674.98

State Avg Cost Per Claim

$14,455.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 45.0
Days Supply 1,350
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills111.8
Peer Average Days Supply3,337
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $680.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.36

State Avg Cost Per Claim

$32.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 43.0
Days Supply 1,290
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills69.2
Peer Average Days Supply2,058
Conservative Utilization

This provider writes prescriptions for this formulation 30.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,382.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.11

State Avg Cost Per Claim

$100.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MICHAEL B VAN SCOY-MOSHER M.D. provides transparency into local medical care patterns within Los Angeles, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.